Literature DB >> 23210543

Mesenteric lymphatic absorption and the pharmacokinetics of naringin and naringenin in the rat.

Yung-Jen Tsai1, Tung-Hu Tsai.   

Abstract

The hypothesis for this study was that flavanoids and their glycoside are absorbed mainly through the portal vein to enter the liver for biotransformation and are only partially absorbed through the lymphatic duct. To verify this hypothesis, an unconscious, mesenteric lymphatic/portal vein/jugular vein/bile duct/duodenum-cannulated rat model was developed. Naringin was administered at dosages of 600 and 1000 mg/kg, and naringenin was given at 100 and 300 mg/kg by intraduodenal administration. Blood samples collected from the portal vein and jugular vein as well as lymphatic fluid were prepared by protein precipitation and then analyzed by high-performance liquid chromatography with photodiode array detection (HPLC-DAD). Analyses of these samples were doubly confirmed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). The results show that, after intraduodenal administration, both compounds were mainly absorbed into portal blood rather than mesenteric lymph, and most of the intact analyte would be eliminated through bile excretion. The area under the concentration (AUC) ratio was defined to represent the absorption ratio for portal vein [AUC(portal)/AUC((portal+lymph))] and lymph fluid [AUC(lymph)/AUC((portal+lymph))]. The results indicate that the portal and lymphatic absorptions for naringin were around 95 and 5.0%, respectively. The respective absorptions for naringenin were around 98 and 2%, respectively.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23210543     DOI: 10.1021/jf301962g

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  8 in total

Review 1.  Nephroprotective activity of naringin against chemical-induced toxicity and renal ischemia/reperfusion injury: A review.

Authors:  Negin Amini; Maryam Maleki; Mohammad Badavi
Journal:  Avicenna J Phytomed       Date:  2022 Jul-Aug

2.  Effects of Jia-Wei-Xiao-Yao-San on the Peripheral and Lymphatic Pharmacokinetics of Paclitaxel in Rats.

Authors:  Mei-Ling Hou; Chia-Ming Lu; Tung-Hu Tsai
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-08       Impact factor: 2.629

3.  Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments.

Authors:  Nabab Khan; Xuesong Chen; Jonathan D Geiger
Journal:  Front Pharmacol       Date:  2020-10-29       Impact factor: 5.810

4.  A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies.

Authors:  Maryam Ghanbari-Movahed; Gloria Jackson; Mohammad Hosein Farzaei; Anupam Bishayee
Journal:  Front Pharmacol       Date:  2021-03-29       Impact factor: 5.810

5.  Possible Therapeutic Use of Natural Compounds Against COVID-19.

Authors:  Nabab Khan; Xuesong Chen; Jonathan D Geiger
Journal:  J Cell Signal       Date:  2021

Review 6.  Meticulous parade on naringin respecting its pharmacological activities and novel formulations.

Authors:  Mahboob Alam; Farogh Ahsan; Tarique Mahmood; Arshiya Shamim; Saba Parveen; Mohammad Shariq; Vaseem Ahmad Ansari
Journal:  Avicenna J Phytomed       Date:  2022 Sep-Oct

7.  Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative.

Authors:  Samaa Alrushaid; Casey L Sayre; Jaime A Yáñez; M Laird Forrest; Sanjeewa N Senadheera; Frank J Burczynski; Raimar Löbenberg; Neal M Davies
Journal:  Pharmaceutics       Date:  2017-09-13       Impact factor: 6.321

8.  Pharmacokinetics and Metabolism of Naringin and Active Metabolite Naringenin in Rats, Dogs, Humans, and the Differences Between Species.

Authors:  Yang Bai; Wei Peng; Cuiping Yang; Wei Zou; Menghua Liu; Hao Wu; Loudi Fan; Peibo Li; Xuan Zeng; Weiwei Su
Journal:  Front Pharmacol       Date:  2020-03-27       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.